SSTR2 and neuroendocrine carcinoma: Somatostatin receptor type 2 (SSTR2) expression was analyzed in 15 NET G3 and 37 NEC cases and found positive or partially positive in 10/15 (67%) of informative NET G3 and 30/37 (81%) of informative NEC lesions.